Medtronic Completes CathWorks & Anteris Deals

Published: February 17, 2026

Medtronic plc

Direct News

Ticker: MDT — Medtronic plc completed acquisitions of CathWorks and Anteris in Q3 FY26 (reported as of 2026-02-17).
Cardiovascular remains Medtronic's largest segment: $10,179 million (38.3%) of total net sales for the 9 months ended Jan 23, 2026.
Filings previously disclosed an option to acquire CathWorks (Feb 2026) with consideration up to $585 million plus contingent payments.
No transaction value for Anteris disclosed in the provided materials.
Medtronic's strategic plan includes expanding Coronary & Peripheral Vascular capabilities and funded R&D partnerships (e.g., Blackstone).

Historical Context

These acquisitions occur against a backdrop of active portfolio and governance moves at Medtronic. Relevant prior events in the provided record include: - Dec 2025: Announcement of the MiniMed separation program as part of portfolio optimization (management expects separation activity to continue into mid-2027). - Nov 3, 2025: Executive Vice President retirement with equity compensation acceleration. - Oct 21, 2025: Re-election of twelve Board directors and approved changes to shareholder rights and voting structure at the AGM. - Filings through FY2025 and the nine months ended Jan 23, 2026, show Cardiovascular as the largest revenue contributor and note an option to acquire CathWorks (Feb 2026) with consideration up to $585 million plus contingent payments; the company reports the CathWorks and Anteris acquisitions as completed in Q3 FY26. Investors evaluating the impact of these transactions should consider how Medtronic allocates purchase accounting, the timeline for integration, any incremental amortization or restructuring charges, and ongoing legal, regulatory and tax exposures disclosed in company filings.

Deal summary and immediate implications

Medtronic announced completion of two cardiovascular acquisitions — CathWorks and Anteris — in Q3 FY26. CathWorks had been disclosed in company filings as an option announced in Feb 2026 with potential consideration up to $585 million plus contingent consideration; the company reports the transaction closed within the quarter. No purchase price or deal terms for Anteris are provided in the materials supplied. Taken together, the deals are presented as portfolio-strengthening moves within Medtronic's Cardiovascular Portfolio, which accounted for $10,179 million (38.3%) of net sales for the nine months ended Jan 23, 2026. Management's stated strategy includes expanding Coronary & Peripheral Vascular capabilities; these acquisitions align with that objective without contradicting the company's existing segmentation or capital-allocation priorities.

Financial context — scale, capital and operating considerations

Medtronic reported total net sales of $26,557 million for the nine months ended Jan 23, 2026, with the Cardiovascular segment representing the largest share. The company is executing portfolio optimization and ongoing restructuring (including the MiniMed separation announced Dec 2025) while managing debt of $28,691 million and FY2025 interest expense of $913 million. Recent capital-allocation initiatives include a $5.0 billion share repurchase authorization and funded R&D arrangements (notably with Blackstone) that may influence future product pipelines. The filings show material intangible amortization (e.g., purchased technology and patents) and IPR&D activity ($150 million IPR&D activated in FY2025); acquisitions historically affect amortization and may result in purchase-accounting intangibles and related amortization in future reporting periods. The company has also disclosed restructuring and transaction-related costs as part of its non-GAAP adjustments.

Strategic fit and operational risks

Medtronic's stated strategy emphasizes portfolio optimization and growth in Coronary & Peripheral Vascular technologies. The CathWorks acquisition (previously disclosed as an option with a potential $585 million cap) was identified in filings as linked to coronary disease diagnostics; the Anteris acquisition is presented as an additional cardiovascular capability. These moves are consistent with management's three-year priorities to expand the Cardiovascular Portfolio and integrate AI/data analytics into product offerings. Risks that may affect the integration and benefit realization include ongoing legal and regulatory exposures (product liability litigation across Massachusetts, Minnesota, and federal MDL; antitrust litigation; SEC/DOJ anti-corruption inquiries), tax contingencies (approximately $2.0 billion of unrecognized tax benefits net of cash advances), and operational pressures such as EU MDR compliance costs and currency impacts. Medtronic also disclosed accrued rebates (~$1.0 billion) and noted no clear cost-advantage moat, underscoring execution risk amid pricing pressure.

Investor FAQ

The most effective approach is to maintain a factual perspective. Keep a close watch on further developments at Medtronic plc as they unfold. Use primary source data to validate your investment thesis rather than relying on delayed secondary reports.

You can set up an automated tracker on Portrak. Our system monitors official SEC filings in real-time, delivering the most critical insights to your phone or inbox seconds after publication—frequently before the information reaches major financial news platforms.

We believe quality intelligence should be accessible. Our business model is supported by professional investors with large, complex portfolios who utilize Portrak Pro. These users pay to automate the monitoring of extensive watchlists, saving hundreds of hours in research time, which allows us to keep the standard service free for individual investors tracking their core positions.

Setting up your automated intelligence pipeline is a simple 3-step process:

Create Your Free Account

Select Your Focus

Use the search bar to find companies like Medtronic plc. Choose between monitoring specific events or receiving general market-moving intelligence. Our AI automatically determines what’s critical based on real-time market data and the company’s current profile.

Receive Real-Time Intelligence

Once activated, all official filings are analyzed instantly. Insights are delivered directly to your email or as a push notification if you use the Portrak mobile app.

Also available as a mobile app for iOS & Android—search for "Portrak"

More Strategic Insights

MDT

Feb 17, 2026

Direct News

Historical Context

Deal summary and immediate implications

Financial context — scale, capital and operating considerations

Strategic fit and operational risks

Investor FAQ

More Strategic Insights

Medtronic Reports Strategic Growth Shift (Q3 FY26)

Medtronic Q3 Report: Growth, Guidance Upheld

Medtronic Issues $419M in New Shares — MDT

Medtronic Issues $419M in New Shares (MDT)